EPI-001 is a BPA-derived experimental drug that is antagonistic to the intrinsically disordered amino-terminus domain of the androgen receptor. EPI-001 is being developed by the pharmaceutical company ESSA Pharma Inc (Vancouver Canada) for the treatment of castration-resistant prostate cancer and is currently in pre-clinical development.
This page contains content from the copyrighted Wikipedia article "EPI-001"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
